Section Arrow
NBP.NASDAQ
- NovaBridge Biosciences
Quotes are at least 15-min delayed:2026/01/09 12:05 EST
Regular Hours
Last
 3.6892
-0.1008 (-2.66%)
Day High 
3.8384 
Prev. Close
3.79 
1-M High
5.19 
Volume 
602.77K 
Bid
3.68
Ask
3.69
Day Low
3.63 
Open
3.8 
1-M Low
3.71 
Market Cap 
436.95M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.13 
20-SMA 4.14 
50-SMA 4.18 
52-W High 6.79 
52-W Low 0.595 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.51/-0.38
Enterprise Value
436.95M
Balance Sheet
Book Value Per Share
1.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
-221,563,000
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1004-0.0029-2.81%-- 
SLSSELLAS Life Sciences Group3.4338-0.4262-11.04%-- 
IBIOiBio2.655+0.305+12.98%0.65PE
MREOMereo BioPharma Group plc0.412+0.0276+7.18%-- 
ARDXArdelyx7.725+0.725+10.36%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.